Skip to main content
TipRanks
Go Ultimate75% OFF

Niagen Bioscience (OCD1) AI Stock Analysis

2 Followers
DE:OCD1

Niagen Bioscience

(Frankfurt:OCD1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Conservative Balance SheetVery low leverage and substantial equity growth provide financial resilience and flexibility. This reduces balance-sheet pressure while allowing Niagen to continue funding product development, market expansion, and clinical programs without relying heavily on debt financing.
Negative Factors
Cooling Revenue and Cash-Flow MomentumRecent revenue contraction and sharply lower operating cash flow indicate that the business is not currently converting its commercial platform into growth at the prior pace. If sustained, weaker momentum could limit internally funded investment and reduce operating leverage.

Niagen Bioscience (OCD1) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:OCD1-66.90%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 163.54M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
16.3
Beta (1Y)
1.07
Revenue Growth
-6.71%
EPS Growth
-53.86%
Country
Germany
Employees
117
Sector
Consumer Defensive
Sector Strength
62
Industry
Biotechnology

Niagen Bioscience Business Overview & Revenue Model

Company Description

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...

Niagen Bioscience Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:1.08%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was broadly constructive, supported by positive operating cash flow, a debt-free balance sheet, resilient direct-to-consumer demand, expanded distribution, progress in skincare and Niagen Plus, and advancing pharmaceutical and scientific programs. These positives were tempered by a 10% year-over-year decline in Tru Niagen revenue, increased competition, a 160 basis point gross-margin decline, a quarterly net loss and higher expected spending.

Positive Updates

Positive Cash Flow and Debt-Free Balance Sheet
Niagen generated approximately $2.6 million in positive operating cash flow and $455,000 of adjusted EBITDA in the third quarter. The company ended the quarter with $69.5 million in cash, no debt and $83.3 million in working capital, a $600,000 increase.

Negative Updates

Tru Niagen Revenue Decline
Third-quarter net sales were $27.2 million, with Tru Niagen contributing $23.3 million, a decrease of 10% or $2.7 million year-over-year. Distribution revenue reflected the timing of Watsons orders and the absence of a sizable order from a large health care practitioner distribution partner received in the prior-year quarter.

Company Guidance

Niagen Bioscience said each business is well positioned for significant growth in 2027, expects fourth quarter revenue to improve sequentially from the third quarter, expects to begin commercialization of a new NR salt form in early 2027, expects a topical product incorporating Niagen to reach the market in early 2027, plans to launch a new branded skin care product in the first half of 2027, and plans to begin first-in-human studies of NB4168 in 2027, subject to completion of the necessary development work and regulatory clearance; the company is presently thinking about 5,000 participants and a 3-year term for the Mass General Brigham prevention trial, expects China cross-border sales to be more than 2 to 3x compared to last year, expects malate to reduce cost of goods in some way in 2027 and in a significant way after that, and expects increased selling and marketing expenses, R&D investments and G&A spending.

Niagen Bioscience Risk Analysis

Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.We face significant competition, including from other supplements such as NMN.Q2, 2026

Niagen Bioscience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

DE:OCD1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
ALECALEC58Neutral$378.15M7.26112.21%―151.23%―
ACOGACOG49Neutral$182.94M-6.10-53.52%―171.93%0.11%
ACIUACIU45Neutral$216.78M-4.45-104.05%―384.77%38.30%
BIOABIOA41Neutral$255.07M-2.18-31.42%―45.33%-20.81%

* Consumer Defensive Sector Average

Performance Comparison

0%100%200%DE:OCD1ACIUALECACOGTELOBIOADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:OCD1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:OCD1Niagen Bioscience, Inc.1.87-3.78-66.90%
ACIUAC Immune2.13-0.97-31.29%
ALECAlector2.541.30104.84%
ACOGAlpha Cognition Inc8.302.4040.68%
TELOTelomir Pharmaceuticals, Inc.0.49-0.91-65.00%
BIOABioAge Labs, Inc.5.55-2.76-33.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.